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Abstract 
The structure of BPSL1549, a protein of unknown function from Burkholderia 
pseudomallei reveals a similarity to E. coli cytotoxic necrotizing factor 1. We 
found that BPSL1549 acted as a potent cytotoxin against eukaryotic cells and 
was lethal when administered to mice. Expression levels of bpsl1549 correlate 
with conditions expected to promote or suppress pathogenicity. BPSL1549 
promotes deamidation of Gln339 of the translation initiation factor eIF4A, 
abolishing its helicase activity and inhibiting translation. We propose to name 
BPSL1549 Burkholderia Lethal Factor 1 (BLF1). 
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The bacterium Burkholderia pseudomallei is the causative agent of 
melioidosis (1) and, in endemic areas including Southeast Asia, can be 
isolated from moist soil and stagnant water. B. pseudomallei infects many 
tissue, causing subclinical infections, acute septicaemia and sub-acute and 
chronic disease. The pathogen has the ability to remain latent in a host for 
decades (2) and infections in troops serving in endemic areas has resulted in 
the pathogen being referred to by the nickname, the “Vietnam Time Bomb” 
(3).  There is no vaccine and the organism is multidrug resistant complicating 
treatment. The molecular mechanisms that underlie disease are largely 
unknown. To address this, a programme of structure determination on 
proteins of unknown function from B. pseudomallei has been initiated.  
  The structure of BPSL1549, a 23 kDa protein of unknown function, 
was determined at 1.04 Å resolution (Table S1, Fig. S1A). The fold consists of 
a sandwich of two curved mixed beta sheets decorated on the outside by 
alpha helices and loops (Fig 1A) and was similar to the catalytic domain of E. 
coli cytotoxic necrotizing factor 1 (CNF1-C) (4) . Eleven strands of the 
BPSL1549 beta sandwich have identical sequence order and direction to 
those of CNF1-C, with an rmsd of 3.9 Å for 170 superposed α-carbon atoms 
(Fig. 1B). However, on the peripheries of the structures there are differences 
in both the extensions to the β-strands and the helices and loops, with only 
one helix in common.  
CNF1-C inactivates Rho GTPases by deamidation of a glutamine 
necessary for GTPase hydrolysis, thereby affecting actin cytoskeleton 
assembly (5). CNF1-C and BPSL1549 showed virtually no sequence identity, 
except at the active sites where the LSGC motif of CNF1-C was conserved in 
BPSL1549 (Fig. S1B,C). The cysteine of this motif, Cys866/ Cys94 in CNF1-C 
and BPSL1549, respectively, is the crucial nucleophile in the CNF1-C catalytic 
triad responsible for deamidase activity (4). His881, the second component of 
the CNF1-C triad was present in BPSL1549 (as His106) and superposed well 
(Fig. 1C). In CNF1-C the third component of the triad is a main chain carbonyl, 
but in BPSL1549 the OG1 of Thr88 hydrogen bonds to the histidine. A 
structurally conserved tyrosine (Tyr164 in BPSL1549, Tyr962 in CNF1-C) 
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hydrogen bonds to the main chain carbonyl of the catalytic cysteine (Fig. 1C).  
The conservation of key catalytic residues with CNF1-C, suggested 
BPSL1549 was a glutamine deamidase. However, the molecular surface 
around the BPSL1549 active site cavity was broader and shallower than that 
of CNF1-C suggesting the deamidation target was different (Fig S2). 
Nevertheless, the structure implied that, like CNF1-C, BPSL1549 might be 
cytotoxic. Intraperitoneal injection of Balb/C mice with BPSL1549 was lethal 
by day 14 (Supplementary online material). BPSL1549 was also toxic to J774 
macrophage cells within 3 days (Fig. 2A).  In contrast, growth of 3T3 cells was 
insensitive to BPSL1549 unless the protein delivery reagent BioPORTER was 
included (Fig. S3A). The differential sensitivity between macrophages and 
fibroblasts may reflect uptake by active macropinocytosis in macrophages, 
although how the toxin accesses the cytoplasm is unclear.  
On the basis of the abolition of the biological activity of CNF1 when 
Cys866 is mutated to serine, a BPSL1549C94S mutant was created. In mice 
BPSL1549C94S was non-toxic, whereas in J774 cells some toxicity (p < 0.05) 
was observed, but only at the highest toxin concentration tested (Fig 2A). 
Thermal stability studies (Fig. S3B,C) together with the BPSL1549C94S 
structure (Table S1) confirmed that this point mutation does not disrupt the 
structure and that C94  is required for BPSL1549 activity.  
To investigate a role for bpsl1549 in bacterial virulence, an in-frame 
deletion mutant of bpsl1549 in B. pseudomallei was constructed. Whilst we 
cannot exclude the influence of polarity effects in the Δbpsl1549 strain,  
compared to the wild type strain the mutant was significantly attenuated when 
mice were challenged by the i.p. route (Fig. 2B).  The median lethal dose of  
B. pseudomallei Δbpsl1549 was 1.26 x 105 colony forming units (CFU), 100 
times higher than that for the wild type B. pseudomallei strain K96243, 
consistent with a role for bpsl1549 in virulence. Moreover, bpsl1549 
expression was highly upregulated in response to multiple virulence cues (Fig. 
S4).  
An affinity column was used to purify BPSL1549 binding-partners from 
human cell extract. The major protein purified was translation initiation factor 
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eIF4A which was confirmed by immunoblotting (Fig. 3A). Interaction with 
endogenous eIF4A was verified by coimmunoprecipitation with FLAG-
BPSL1549. FLAG-BPSL1549C94S precipitated more eIF4A than FLAG-
BPSL1549, suggesting that release of the substrate from the toxin requires 
completion of deamidation (Fig. 3B).  
The BPSL1549:eIF4A interaction suggested BPSL1549 might inhibit 
translation and its expression in human cells led to 90% or greater reduction 
in gene expression for two reporters.  Reduced translation inhibition by 
BPSL1549C94S may result from binding eIF4A (Fig. 3B,C).  The reporter 
mRNA levels were unaffected, consistent with BPSL1549 blocking translation 
(Fig. 3C, right panel). BPSL1549 reduced endogenous protein synthesis 
monitored by 35S-Met/Cys incorporation at levels similar to that seen with the 
eIF4A inhibitor hippuristanol (6), whereas BPSL1549C94S did not (Fig. 3D). 
The ongoing translation in the presence of BPSL1549 may arise from eIF4A-
independent mRNAs. To assess the impact of BPSL1549 on translation 
initiation we monitored the abundance of ribosomal subunits, monosomes and 
polysomes in cell extracts (Fig. 3E).  BPSL1549 enhanced the size of the 80S 
peak and reduced the size of the polysome peaks with polyA binding protein 
(PABP) being absent in this region of the gradient. This suggested translation 
initiation was stalled , mirroring the situation seen with the eIF4A specific 
inhibitor pateamine A (7).   
A translational block can trigger cytoplasmic stress granule formation 
either by an eIF2α phosphorylation-dependent or independent pathways 
induced by cellular stresses or by inactivation of eIF4A, 4G, 4B,4H or PABP 
respectively (8). Sodium arsenate treatment led to both stress granule 
formation and eI ). BPSL1549 expression also 
caused stress granule formation, but not eIF2α phosphorylation, consistent 
with activation of the eIF2α phosphorylation-independent pathway. 
BPSL1549C94S failed to trigger stress granule formation efficiently, 
consistent with its reduced ability to inhibit translation.  
To identify the modification in eIF4A we used MS to analyse FLAG-
eIF4AI purified from human cells expressing BPSL1549 (Fig. S6). MS 
revealed deamidation of Gln339 to Glu (Fig. 4A). Gln339 is in the C-terminal 
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domain of eIF4A and is the first glutamine of a conserved Gln-Gln pair lying 
between motifs V and VI (9). This loop is adjacent to the cleft between the 
enzyme’s two domains and lies between the ATP and RNA binding sites (Fig 
S7) suggesting modification might  inhibit eIF4A ATPase or helicase activities. 
In vitro, BPSL1549 deamidates eIF4A Gln339 with a turnover number of ~700 
per minute, similar to the rate of depurination catalysed by ricin (10) (Fig. S8, 
S9). Consistent with Gln339 being the target residue, BPSL1549 binds less 
efficiently to eIF4AIQ339E, the product of the deamidation reaction (Fig. S10).  
Two isoforms of eIF4A (I and II) have a glutamine at position 339, whereas 
eIF4AIII, an exon junction complex subunit, has proline at this position and is 
unlikely to be a BPSL1549 substrate.  
Expression of  eIF4AI Q339E in vivo reduced expression of two 
reporters, indicating Q339E is dominant negative, whereas control mutation 
Q340E had no effect (Fig. 4B).  Q339E had no effect on eIF4A1 ATPase 
activity or RNA and ATP binding (Fig. S11). However, Q339E reduced RNA 
helicase activity (Fig. 4C). eIF4AI mutations that uncouple the ATPase and 
helicase activities are known to act as inhibitors of translation (11). At molar 
ratios of 1:500 BPSL1549:eIF4A there was 47% inhibition of helicase activity 
indicative of enzymatic modification by BPSL1549. Whereas BPSL1549C94S 
only caused 15% inhibition of helicase activity at a molar ratio of 1:10 
BPSL1549C94S:eIF4A, probably caused by BPSL1549C94S binding to eIF4A 
(Fig S12). Based on the closed conformation structure of eIF4AIII (12), Gln339 
in eIF4AI would lie close to Asp337 and Arg368 and the 3’ adenine ribose 
hydroxyl of ATP (Fig. S13). Thus, deamidation of Gln339 probably disrupts 
interaction between these residues, influencing the functions of Asp337. In the 
Vasa RNA helicase, the structural equivalent of eIF4AI Asp337 is Asp534 and a 
D534A mutation uncouples ATP hydrolysis and RNA binding from the 
helicase activity (13).  
We examined the impact of BPSL1549 on formation of the cap binding 
complex eIF4F. BPSL1549 had no impact on the levels of eIF4E, 4G1 or 
PABP bound, but increased the amount of eIF4A recovered (Fig. 4D), 
suggesting eIF4A was more stably bound within eIF4F. Endogenous eIF4A 
was readily exchanged with recombinant eIF4A within eiF4F when cell 
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extracts were pre-incubated with the control splicing factor SC35 (Fig. 4E 
lanes 6,7) but in cell extracts pre-incubated with BPSL1549,  recombinant 
eIF4A did not efficiently displace endogenous eiF4A from eIF4F. Thus 
recycling of eIF4A, required for efficient translation (11),(14) would be 
impaired.   
Compared to CNF1-C a major difference with BPSL1549 is the lack of 
the receptor binding and translocation domains, essential for cytoplasmic 
delivery of CNF1-C. However, the intracytoplasmic lifestyle of B. pseudomallei 
removes the need for BPSL1549 to cross the eukaryotic cell membrane, 
though the absence of an obvious BPSL1549 signal sequence leaves its 
mechanism of secretion uncertain. The demonstration that BPSL1549 is a 
potent inhibitor of translation suggests that it is an important weapon in the 
armoury of B. pseudomallei and we suggest renaming it Burkholderia Lethal 
Factor 1 (BLF1). The identification of  structurally unrelated papain-like 
glutamine deamidases CHBP in B. pseudomallei (15) and PMT in Pasteurella 
multocida (16) suggests this type of chemistry may be more generally 
employed by pathogenic bacteria than is currently recognised.  
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Figure Legends 
Fig. 1 Structural analysis of BPSL1549 (A) Cartoon representation of 
BPSL1549 with helices and strands numbered. (B) Cartoon representation 
showing the similarity in overall fold between BPSL1549 (blue) and CNF1-C 
(red). (C)  Detail of superposition of BPSL1549 (pale blue) and CNF1-C (pale 
red) around their active sites with residues strongly conserved between the 
two toxins, including the critical cysteine and histidine, highlighted. Hydrogen 
bonds shown as dotted lines. 
Fig. 2 Toxic effects of BPSL1549 (A) Effect of BPSL1549 and C94S mutant 
on the BALB/c J774.2 macrophage cell line after 72h. Values correspond to 
the means of  three to seven  independent experiments performed in duplicate 
and error bars represent S.D. Data were analysed by ANOVA and values 
significantly different from control (no toxin) are shown as *** p < 0.0001; * p < 
0.05. Significant toxic effects were evident at concentrations down to 2.5 x 10-
7 M (5.7 g.ml-1) with an EC50 of 2.7 x 10
-7M (6.2 g.ml-1). (B) Survival of 
BALB/c mice (n=6) challenged with 4.2 x 104 cfu/ml B. pseudomallei K96243 
(●) or 5.8 x 104 cfu/ml B. pseudomallei K96243∆BPSL1549 (■) (p<0.001).  
 
Fig. 3 BPSL1549 modifies eIF4A and blocks translation (A) SDS-PAGE 
analysis of human proteins eluted from a 6xHisBPSL1549 affinity column 
using NaCl elution buffer. The control protein was 6xHis YloQ (GTPase from 
B.subtilis). The major band was identified by mass spectrometry (MS) as 
eIF4A and confirmed by immunoblotting (lower panel). (B) Co-
immunoprecipitation of FLAG-BPSL1549 or FLAG-BPSL1549C94S using 
FLAG antibody with endogenous eIF4A. FLAG-BAP (bacterial alkaline 
phosphatase) was used as a control. (C) Reporter gene assays 24 hours 
post-transfection with FLAG-BPSL1549 or FLAG-BPSL1549C94S. Enzyme 
assays (left panel) and qRT-PCR analysis of reporter mRNA levels (right 
panel). RT = reverse transcriptase. (D) 35S-Met/Cys incorporation into proteins 
in 293T cells following transfection with control FLAG-BAP, FLAG-BPSL1549 
or FLAG-BPSL1549C94S. (E) Polysome analysis of 293T cell extracts from 
cells transfected with FLAG or FLAG-BPSL1549 vectors. The lower panels 
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show immunoblots of fractions with a PABP antibody. Error bars represent the 
S.D. from three independent experiments.  
Fig. 4. BPSL1549 inhibits eIF4AI RNA helicase activity  (A) Tandem MS 
analysis of the deamidated peptide GIDVEQVSLVINYDLPTNR [M+2H] 2+ 
from eIF4A. The prominent b and y ions are highlighted. Inset shows an 
expanded view of the intact mass of the [M+2H] 2+ peptide (B) Reporter genes 
were cotransfected with wild type or Q339E eIF4AI and enzyme activities 
measured. FLAG-eIF4AI construct expression was confirmed by 
immunoblotting (lower panel). Error bars represent S.D. from three 
independent experiments. (C) RNA helicase assays with eIF4AI and mutants 
(upper panel); the lower panel shows quantification from 3 separate helicase 
assays with S.D. shown by error bars. Helicase activity in % = 
(ssRNA)/(dsRNA + ssRNA)*100. eIF4B stimulates the helicase activity of 
eIF4AI. UAP56 is a control RNA helicase and Magoh, a component of the 
exon junction complex, is a non RNA binding control. (D) Purification of eIF4F 
using methyl-7 GTP sepharose and Protein G sepharose as control. eIF4F 
components were identified by immunoblotting. (E) eIF4AI recycling assay. 
eIF4F was purified from extracts treated with BPSL1549 or SC35 (control) as 
indicated.  Following purification, recombinant eIF4AI was added to eIF4F 
bound to methyl-7 GTP sepharose. Proteins were identified by 
immunoblotting. WCE = whole cell extract.  
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